使用现实世界的数据预测对GLP-1通路药物的反应性
Xiaodong Zhu1,2, Michael J Fowler2, Quinn S Wells2,3
1Department of Veterans Affairs, Tennessee Valley Health Authority, Nashville, TN, USA.
BMC endocrine disorders
|December 19, 2024
概括
使用电子健康记录的预测模型确定了最有可能从2型糖尿病的葡萄糖类-1 (GLP-1) 途径药物中受益的患者子组. 较高的治疗前HbA1C预测了更好的反应,而某些其他药物与较差的结果相关.
科学领域:
- 糖尿病研究研究 糖尿病研究
- 药物基因组学 药物基因组学
- 医疗信息学 医疗信息学
背景情况:
- 葡萄糖类-1 (GLP-1) 途径药物对2型糖尿病 (T2D) 管理至关重要.
- 确定从GLP-1药物中获益最多的患者子组仍然是一个挑战.
研究的目的:
- 开发一种对GLP-1药物 (GLP-1受体激动剂和DPP4抑制剂) 患者反应的预测模型.
- 根据患者特征指导临床医生选择二线T2D治疗.
主要方法:
- 分析了7856名T2D患者 (2003-2019) 的非识别电子健康记录.
- 逻辑回归,LightGBM,人工神经网络和支持矢量分类器模型的比较.
- 包括临床特征,实验室测试,人口统计和糖尿病并发症.
主要成果:
- 后勤回归模型实现了0.77的auROC,优于其他机器学习模型.
- 较高的治疗前HbA1C预测了对GLP-1药物的更好的反应.
- 使用 thiazolidinediones 或硫尿素与反应较差相关.
- 在40岁以下的女性患者中,NSAID使用与较大的HbA1C降低有关.
结论:
- 现实世界的数据分析可以改进T2D治疗决策.
- 预测模型强调个体患者的特征和药物相互作用,以优化GLP-1药物处方.
相关概念视频
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Analysis of Population Pharmacokinetic Data
224
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
224
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773


